Abstract
Previous data demonstrated that an elevated percentage of hepatitis C virus (HCV) infected patients are endotoxemic. Endotoxemic patients are poor responders to the interferon (IFN)- α / ribavirin (RIB) treatment and exhibit lower serum levels of IFN-γ and interleukin (IL)-10 than the responder counterpart. Here we provide evidence that in endotoxemic HCV+ patients absolute numbers of CD19+ cells (B cells) are higher than those observed in the non-endotoxemic counterpart at the end of the combined treatment. Moreover, anti lactoferrin (LF) antibodies are more elevated in non-responder HCV+ patients than in the responders. In turn, these autoantibodies may affect the antiviral activity of LF, on the one hand , and, on the other hand abrogate the LF binding to lipopolysaccharides (LPS). Such an interaction hampers the binding of LPS to LPS binding protein, thus inhibiting LPS fixation to CD14+ cells and, ultimately, leading to a decreased release of proinflammatory cytokines.
Keywords: hepatitis c virus, interferon-a, ribavirin, b iymphocytes, endotoxins
Current Pharmaceutical Design
Title: The Immune Responsiveness in Hepatitis C Virus Infected Patients: Effects of Interferon-Alfa / Ribavirin Combined Treatment on the Lymphocyte Response with Special Reference to B Cells
Volume: 10 Issue: 17
Author(s): L. Amati, R. Cozzolongo, O. G. Manghisi, R. Cuppone, N. M. Pellegrino, D. Caccavo and E. Jirillo
Affiliation:
Keywords: hepatitis c virus, interferon-a, ribavirin, b iymphocytes, endotoxins
Abstract: Previous data demonstrated that an elevated percentage of hepatitis C virus (HCV) infected patients are endotoxemic. Endotoxemic patients are poor responders to the interferon (IFN)- α / ribavirin (RIB) treatment and exhibit lower serum levels of IFN-γ and interleukin (IL)-10 than the responder counterpart. Here we provide evidence that in endotoxemic HCV+ patients absolute numbers of CD19+ cells (B cells) are higher than those observed in the non-endotoxemic counterpart at the end of the combined treatment. Moreover, anti lactoferrin (LF) antibodies are more elevated in non-responder HCV+ patients than in the responders. In turn, these autoantibodies may affect the antiviral activity of LF, on the one hand , and, on the other hand abrogate the LF binding to lipopolysaccharides (LPS). Such an interaction hampers the binding of LPS to LPS binding protein, thus inhibiting LPS fixation to CD14+ cells and, ultimately, leading to a decreased release of proinflammatory cytokines.
Export Options
About this article
Cite this article as:
Amati L., Cozzolongo R., Manghisi G. O., Cuppone R., Pellegrino M. N., Caccavo D. and Jirillo E., The Immune Responsiveness in Hepatitis C Virus Infected Patients: Effects of Interferon-Alfa / Ribavirin Combined Treatment on the Lymphocyte Response with Special Reference to B Cells, Current Pharmaceutical Design 2004; 10 (17) . https://dx.doi.org/10.2174/1381612043384231
DOI https://dx.doi.org/10.2174/1381612043384231 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pulmonary Infections in the Era of Biological Agents
Current Respiratory Medicine Reviews Editorial [Hot Topic: Targeting Tumor Uniquitin-Proteasome Pathway with New and Old Drugs (Guest Editor: Q. Ping Dou)]
Current Cancer Drug Targets Advances in Clinical Study of Curcumin
Current Pharmaceutical Design Human Hematopoietic Stem Cells in Gene Therapy: Pre-Clinical and Clinical Issues
Current Gene Therapy Glycolipid Stimulators for NKT Cells Bearing Invariant Vα19-Jα33 TCR α Chains
Mini-Reviews in Medicinal Chemistry Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry Targeted Liposomal Drug Delivery in Cancer
Current Pharmaceutical Design Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging Interferon Treatment in Patients with Hypereosinophilia
Current Drug Targets The Molecular Pathology of Eye Tumors: A 2019 Update Main Interests for Routine Clinical Practice
Current Molecular Medicine Astatine Radiopharmaceuticals: Prospects and Problems
Current Radiopharmaceuticals New Aspects of Cyclosporin A Mode of Action: from Gene Silencing to Gene Up-Regulation
Mini-Reviews in Medicinal Chemistry The Stem Cell Factor Receptor/c-Kit as a Drug Target in Cancer
Current Cancer Drug Targets Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems
Current Pharmaceutical Biotechnology Lipid based Nanocarriers for Oral Delivery of Cancer Chemotherapeutics: An Insight in the Intestinal Lymphatic Transport
Drug Delivery Letters Drug Repurposing for the Treatment of Staphylococcal Infections
Current Pharmaceutical Design Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes
Current Pharmaceutical Biotechnology 3D QSAR of Aminophenyl Benzamide Derivatives as Histone Deacetylase Inhibitors
Medicinal Chemistry Infection, Stem Cells and Cancer Signals
Current Pharmaceutical Biotechnology Recent Progress Toward Hydrogen Medicine: Potential of Molecular Hydrogen for Preventive and Therapeutic Applications
Current Pharmaceutical Design